Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin to Build Biologics Manufacturing Site in North Carolina
June 12, 2024
- Maruho Launches Mitchga 30 mg Vial Version in Japan
June 12, 2024
- US FDA Snubs Mitsubishi Tanabe’s Parkinson’s Drug
June 12, 2024
- Takeda Rebuts ISS’ Advice to Vote against Re-Election of CEO Weber
June 11, 2024
- Susana Murteira Tapped as Amgen Japan President
June 11, 2024
- Alecensa Snags EU OK for Adjuvant Setting of ALK-Positive NSCLC
June 11, 2024
- Japan Ethical Drug Sales Up 7.3% in April: Crecon
June 11, 2024
- Keytruda Tops Japan Drug Sales Ranking for 8 Months on End: Encise
June 11, 2024
- Takeda Rolls Out Obizur for Acquired Hemophilia A in Japan
June 11, 2024
- Kissei Grants Korean Rights for GnRH Antagonist Linzagolix to JW
June 11, 2024
- Leqembi’s Monthly IV Dosing Accepted for FDA Review: Eisai
June 11, 2024
- Moderna Files Updated Spikevax for JN.1 Strain in Japan
June 11, 2024
- Rohto Bags Majority Stake in Austria Pharma to Boost European Biz
June 10, 2024
- Towa Files NDA for Rivastigmine Twice Weekly Transdermal Patch in Japan
June 10, 2024
- Novavax COVID Vaccine to Be Adapted to JN.1 Strain: Takeda
June 10, 2024
- Shionogi Gets Option Rights to Cilcare’s Hearing Loss Assets
June 10, 2024
- Maruho Licenses Amenalief Rights in 10 ASEAN States to Singapore Firm
June 7, 2024
- Overseas Sales Ratio of 25 Japan Drug Makers Reaches 67% in FY2023: Tally
June 6, 2024
- TAK-861 Hits Main Goal in PIIb Trial, PIII Set to Begin in 1H FY2024: Takeda
June 6, 2024
- Shionogi to Open Antimicrobial R&D Center in San Diego
June 6, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…